Key Highlights
- BillionToOne slid on Wednesday, closing at $91.54.
- Fuzzy Panda Research disclosed a short position and published a report.
- The company called the report inaccurate and misleading.
- Shares were down more sharply earlier in the session.
A short report and a rebuttal
BillionToOne (NASDAQ:BLLN) slid on Wednesday, closing the regular session at $91.54, as the stock finished among the notable decliners in the FT Wilshire 5000. The shares were down more sharply at one point during the session before recovering some ground.
The session's catalyst was a short-seller report. Fuzzy Panda Research disclosed a short position in BillionToOne and published a report on the company. The company responded with a press release headlined "Inaccurate and Misleading Short Seller Report."
How short reports work
A short seller profits when a stock falls. Firms that take short positions sometimes publish research explaining their view, and those reports can move a stock sharply, particularly when they arrive without warning. Because the publisher stands to benefit if the share price declines, investors often weigh such reports alongside the company's response and other available information.
Companies targeted by short reports frequently issue rebuttals, as BillionToOne did, laying out their own position. The two sides typically present very different views, and it can take time for investors to sort through the arguments. Fuzzy Panda's report and the company's rebuttal represent the views of each party.
What BillionToOne does
BillionToOne is a molecular diagnostics company. It develops genetic tests that analyze small amounts of DNA, with products used in prenatal screening and in oncology, where tests can help doctors monitor cancer. The company became publicly traded relatively recently, which means its shares have a limited trading history and can be more volatile as investors form views on its prospects.
Diagnostics companies are often valued on growth in test volumes, reimbursement from insurers and government programs, and their pipeline of new tests.
A tough day for health care
BillionToOne's decline came during a weak session for health care stocks. Health care was the second-worst-performing sector in the S&P 500, behind energy. Much of that pressure came from health insurers, which sold off for a second straight day after the Centers for Medicare & Medicaid Services proposed expanding Medicare Advantage audits.
The broader market was mixed. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and its longest losing streak since June. The Dow fell 561.25 points to 50,198.17, while the Nasdaq Composite rose 101.50 points to 24,429.88. The Russell 2000 added 12.44 points to 2,714.31. The FT Wilshire 5000 is one of the broadest measures of the US stock market, spanning nearly every actively traded US company.
Minutes from the Federal Reserve's October meeting showed almost all participants judged further increases in the federal funds rate "would likely be appropriate."
A Short Report and a Rebuttal Test BillionToOne Holders
Investors will be watching for any further statements from BillionToOne addressing the short report, as well as any additional commentary from Fuzzy Panda Research. How the stock trades in the coming sessions may show how the market is weighing the two sides.
The company's next Quarterly Report will be an important checkpoint, with attention likely on test volumes, Revenue growth and reimbursement trends. Analyst commentary following the report and the company's rebuttal could also influence the shares.






Please wait processing your request...